CandlesenseCandlesense
STOK•benzinga•

Stoke Therapeutics Q3 2024 GAAP EPS $(0.47) Beats $(0.54) Estimate, Sales $4.89M Beat $3.35M Estimate, $269.2M In Cash, Cash Equivalents, And Marketable Securities

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 5, 2024 by benzinga

← Back to STOK News
Stoke Therapeutics Q3 2024 GAAP EPS $(0.47) Beats $(0.54) Estimate, Sales $4.89M Beat $3.35M Estimate, $269.2M In Cash, Cash Equivalents, And Marketable Securities | STOK Stock News | Candlesense